DexCom, Inc.
DXCM
Pozycja w akcjach
#751
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Cena akcji
$86.01
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$32.45B
Zmiana (1 dzień)
-0.04%
Zmiana (1 rok)
25.68%
Kraj
US
Handel DexCom, Inc. (DXCM)
Kategoria
Healthcare
Zyski dla DexCom, Inc. (DXCM)
Zyski w Jun 2026 TTM: $1.28B
Według najnowszych raportów finansowych DexCom, Inc., obecny zysk firmy wynosi $1.28B. W roku 2024 firma osiągnęła zysk w wysokości $709.00M, spadek w porównaniu do zysku z roku 2023, który wynosił $710.40M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy DexCom, Inc. od 2000 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $1.28B | 17.60% |
| 2025 | $1.09B | 53.51% |
| 2024 | $709.00M | -0.20% |
| 2023 | $710.40M | 81.78% |
| 2022 | $390.80M | 52.18% |
| 2021 | $256.80M | 14.13% |
| 2020 | $225.00M | 115.93% |
| 2019 | $104.20M | -182.37% |
| 2018 | $-126.50M | 160.29% |
| 2017 | $-48.60M | -25.12% |
| 2016 | $-64.90M | 12.87% |
| 2015 | $-57.50M | 157.85% |
| 2014 | $-22.30M | -25.17% |
| 2013 | $-29.80M | -46.59% |
| 2012 | $-55.80M | 24.70% |
| 2011 | $-44.75M | -18.89% |
| 2010 | $-55.17M | 3.08% |
| 2009 | $-53.52M | -3.01% |
| 2008 | $-55.18M | 20.28% |
| 2007 | $-45.88M | -1.55% |
| 2006 | $-46.60M | -99.85% |
| 2005 | $-30.89B | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $7.51B | 486.80% |
US
|
|
| $5.56B | 334.61% |
IE
|
|
| $5.15B | 302.19% |
US
|
|
| $3.86B | 201.64% |
US
|
|
| - | - |
DE
|
